Alethia Biotherapeutics Inc.
logo BDC

Alethia Biotherapeutics Inc.

Alethia is developing innovative therapeutic approaches in areas of unmet medical needs, capitalizing on its capacity to identify and validate disease-specific targets for the development of highly focused monoclonal antibody-based therapeutics. The company is currently focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss.

Investment year:  2008
Industry sector:  Drugs
Region:  Quebec
Website
Follow Alethia Biotherapeutics Inc.

Recent news

Alethia Biotherapeutics submits a clinical trial application (CTA) for a Phase I study with AB-16B5, inhibitor of EMT in patients with advanced cancers

Learn More
BDC Venture Capital Partner

Amine Benmoussa

Principal

v17.9.0.10395